● ImportantWorld2 outlets covering this

Eli Lilly takes aim at illicit market for its experimental weight-loss drug

First publishedAug 12, 10:06 UTC

Last updatedAug 12, 11:57 UTC · just now ago

2 outlets over time — hover a bar for its window & outletslast updated

● Story signals

How strong is this topic?

7.1/10Significanceimpact & urgency

7.5/10Source trustoutlet authority

2Outletsindependent sources

Significance weighs impact, urgency & coverage breadth · Source trust is the outlets' average authority · more outlets means a more confirmed story.

Answer

The pharmaceutical company is filing lawsuits against six outlets selling versions of its promising but unapproved weight-loss drug, retatrutide.

Reported by 2 outlets — CBS News, CNBC Top News. See all sources ↓

Read the full report at CBS News ↗

Why it matters

2 outlets are covering this world story — one to watch as reporting develops.

In brief

What's the story?: The pharmaceutical company is filing lawsuits against six outlets selling versions of its promising but unapproved weight-loss drug, retatrutide.
How widely is it covered?: 2 outlets, average source rating 7.5/10.
When was it last updated?: just now ago.

Different angles across outlets

Coverage map

How outlets are framing the same story

Here's how each outlet is covering the story — compare their headlines and timing at a glance.

Coverage card2 outlets
1Coverage
Scouting report
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Sources2
TypeCoverage
CBS NewsAug 12, 10:06
CNBC Top NewsAug 12, 10:37

Related in the knowledge graph

organizationEli Lilly

Sources (2)

Avg source rating 7.5/10

Processing cluster

A1A2A3B1B2B3

Share this article

X / Twitter LinkedIn WhatsApp

Summarize with AI (opens AI chat with article URL · Gemini: prompt copied to clipboard)

GPT Perplexity Gemini Claude